New BTK Inhibitor Makes Case for Earlier Use in CLL

By News Health
41 minutes Ago

(MedPage Today) — ORLANDO — Patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) lived significantly longer without disease progression when treated with the Bruton’s tyrosine kinase (BTK) inhibitor…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118905

Author :

Publish date : 2025-12-09 15:30:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn't Be Treated; New Mpox Strain

GLP-1s and Cancer: Meta-analysis Shows Little or No Link

Reducing Hospital Readmissions From Nursing Facilities

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

Lower Risk Groups Can Cut Back on Cervical Cancer Screening